Ziopharm Oncology Presents Pre-Clinical Data Validating “Rapid Personalized Manufacture” (RPM) with TCR at the 2019 American Society for Hematology Annual Meeting
– Membrane bound IL-15 (mbIL15) improves anti-tumor effect of TCR-modified T cells –
– T cells expressing T-cell receptor (TCR) and mbIL15 can be infused day after gene transfer –
“These pre-clinical data demonstrate that T cells genetically modified using DNA plasmids from the Sleeping Beauty system to express TCR with membrane bound IL-15 (mbIL15) exhibit anti-tumor effects,” said
Data were presented today in the poster presentation “Rapid Personalized Manufacture (RPM) of Sleeping Beauty System-generated NY-ESO-1-specific TCR-T Cells Co-Expressing Membrane-bound IL-15 Yields Antitumor Responses” and demonstrated:
- T cells can be genetically modified with the Sleeping Beauty system to express TCR and mbIL15;
- T cells expressing TCR and mbIL15 exhibited superior anti-tumor effects compared with TCR-modified T cells without mbIL15;
- T cells expressing TCR and mbIL15 are infused the day after gene transfer per RPM;
- Low-dose of T cells genetically modified per RPM to express TCR and mbIL15 exhibit anti-tumor effects;
- T cells expressing TCR and mbIL15 persist in mouse model.
This proof-of-concept study, reported today at ASH, targets a well-understood antigen (NY-ESO-1) which supports using DNA plasmids from the Sleeping Beauty platform to express TCRs with mbIL15 to improve the manufacture of T cells with specificity for neoantigens. The Company announced in
Learn more about the Sleeping Beauty system online at https://ziopharm.com/t-cell-therapy/tcrs-for-solid-tumors/. The poster presented at the ASH 2019 Annual Meeting will be available on the Company’s website in the “Scientific and Medical Publications” section.
This news release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as "may," "will," "could," "expects," "plans," "anticipates," and "believes." These statements include, but are not limited to, statements regarding the activities and benefits of the collaboration between the Company and MD Anderson, including the Company’s expectations regarding future clinical trials, the potential benefits of T cells expressing TCR with mbIL15 and the progress and timing of the Company's research and development programs. Although Ziopharm’s management team believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Ziopharm, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, changes in our operating plans that may impact our cash expenditures, the uncertainties inherent in research and development, future clinical data and analysis, including whether any of Ziopharm’s product candidates will advance further in the preclinical research or clinical trial process, including receiving clearance from the
VP, Investor Relations and Corporate Communications
Source: ZIOPHARM Oncology Inc